Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
Saved in:
| Title: | Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma. |
|---|---|
| Authors: | Mao Y; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Gide TN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Maher NG; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Vignati D; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Boutros A; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genova, Italy., Cornejo-Páramo P; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Potter AJ; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Westmead and Blacktown Hospitals, Sydney, NSW, Australia., Paver EC; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; The Canberra Hospital, Canberra, ACT, Australia.; College of Science and Medicine, Australian National University, Canberra, ACT, Australia., Burke H; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Mater Hospital, North Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., da Silva IP; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Champalimaud Foundation, Lisbon, Portugal., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Mater Hospital, North Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia., Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2026 Jan 22; Vol. 10 (1), pp. 55. Date of Electronic Publication: 2026 Jan 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-025-01230-y |
